Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females in the developed world. Currently, an important treatment for these patients is the drug Avastin® (bevacizumab), which inhibits tumour blood vessel formation and thus prevents tumour growth.
While molecularly targeted drugs like Avastin offer the ability to manipulate specific molecular interactions, there is the danger that the disease will eventually activate other, previously redundant, cellular pathways, thereby blunting the drug's effectiveness.
Colorectal cancer (CRC) has among the highest cancer mortality rate worldwide, with over 608,700 deaths per year. Annually, over one million new cases are diagnosed worldwide. APO-DECIDE will develop and validate systems-based biomarkers for apoptosis susceptibility. » read more